Why Organigram (TSX:OGI) Is Up 27.1% After Strong FY2025 Results And Bullish 2026 Revenue Guidance

• Organigram Global Inc. has reported its fiscal 2025 results, with sales rising to C$403.02 million and revenue to C$259.18 million, while net loss and loss per share from continuing operations narrowed year on year.
• Alongside record market share in Canadian recreational cannabis and growing international sales, the company has guided for Fiscal 2026 net revenue above C$300 million, supported by new product launches, acquisitions, and cultivation and extraction advances.
• With strong full-year revenue growth and improved profitability, we’ll explore how Organigram Global’s reinforced Canadian leadership and international expansion shape its investment narrative.

These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is Organigram Global's Investment Narrative?

To own Organigram Global, you really need to buy into a turnaround in a still-tough cannabis market, where scale, brands and cost control matter more than headline growth. The latest full-year numbers, with revenue climbing to C$259.18 million and losses narrowing, support the idea that its Canadian leadership and expanding international footprint are starting to translate into a more efficient business. The company’s guidance for Fiscal 2026 net revenue above C$300 million, coupled with margin expansion ambitions, sharpens near-term catalysts around execution on acquisitions, beverages and new product platforms like FAST™. At the same time, the stock’s strong recent run suggests expectations have moved higher, so any stumble on integration, pricing pressure, or further non-cash hits to earnings could quickly refocus attention on risk rather than recovery.

However, there is one big execution risk here that shareholders should keep front of mind. Organigram Global's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Four Simply Wall St Community fair value estimates span a wide C$3.00 to about C$23.37 range, underlining how differently people see Organigram’s path. Set that alongside the recent revenue surge and still-present profitability risk, and it becomes clear why you may want to weigh several viewpoints before deciding what the latest guidance really means for the business.

Explore 4 other fair value estimates on Organigram Global - why the stock might be worth over 8x more than the current price!

Build Your Own Organigram Global Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Organigram Global research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Organigram Global research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Organigram Global's overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
• Find companies with promising cash flow potential yet trading below their fair value.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com